Adenosquamous Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADN009 MIFTS: 49	Adenosquamous Carcinoma Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma ¹² ¹⁵ ¹⁷ ⁷⁰

Mixed Adenocarcinoma and Squamous Carcinoma ¹²

Adenosquamous Cell Carcinoma ¹²

Carcinoma, Adenosquamous ⁴⁴

Carcinoma Adenosquamous ⁵⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4830

MeSH ⁴⁴ D018196

NCIt ⁵⁰ C3727

SNOMED-CT ⁶⁷ 403902008

EFO ¹⁷ EFO_1000073

UMLS ⁷⁰ C0206623

Sources

Summaries for Adenosquamous Carcinoma

Disease Ontology : ¹² A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to esophageal adenosquamous carcinoma and adenosquamous lung carcinoma. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Developmental Biology and Gastric cancer. The drugs Doxorubicin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include cervix, pancreas and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷³ Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Sources

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 650)

#	Related Disease	Score	Top Affiliating Genes
1	esophageal adenosquamous carcinoma	32.5	TP53 KRT7 KRT5 CEACAM5
2	adenosquamous lung carcinoma	32.3	PIK3CA KRAS EGFR
3	tubular adenocarcinoma	31.0	MUC1 KRT7 EGFR CEACAM5
4	subareolar duct papillomatosis	30.7	KRT8 KRT7 KRT5
5	cervical adenocarcinoma	30.7	TP53 KRT7 KRAS EGFR CEACAM7 CEACAM5
6	pancreatic ductal adenocarcinoma	30.7	TP53 SMAD4 MUC1 KRAS EGFR CDKN2A
7	gallbladder adenocarcinoma	30.7	TP53 PIK3CA EGFR
8	cystadenoma	30.7	SERPINA3 MUC1 KRT7 CEACAM5
9	appendix adenocarcinoma	30.6	SMAD4 KRT7 KRAS
10	signet ring cell adenocarcinoma	30.6	TP53 MUC1 KRT7 KRAS CEACAM5
11	intrahepatic cholangiocarcinoma	30.6	TP53 SMAD4 MUC4 MUC1 KRT7 KRT19
12	squamous cell papilloma	30.6	TP53 CDKN2A
13	leukoplakia of penis	30.5	KRT7 CEACAM5
14	mature teratoma	30.5	TP53 KRT7 KRAS CEACAM5
15	bile duct cysts	30.5	KRT7 KRT19 KRAS CEACAM5
16	klatskin's tumor	30.5	TP53 KRT7 KRT19 CEACAM5
17	oral cancer	30.5	TP53 KRT19 EGFR CDKN2A
18	gallbladder squamous cell carcinoma	30.5	KRT5 CEACAM5
19	skin benign neoplasm	30.4	TP63 SERPINA3 KRT7 KRT5
20	bile duct cystadenocarcinoma	30.4	MUC1 KRT7 CEACAM5
21	pancreatic adenocarcinoma	30.4	TP53 SMAD4 PIK3CA MUC4 KRAS EGFR
22	mucoepidermoid esophageal carcinoma	30.4	TP53 KRT5 CEACAM5
23	barrett esophagus	30.4	TP53 SMAD4 KRT7 CDKN2A AR
24	gastric squamous cell carcinoma	30.3	SERPINA3 KRT7 KRT5
25	cervical cancer	30.3	TP63 TP53 SMAD4 PIK3CA KRT19 CDKN2A
26	gastric adenocarcinoma	30.3	TP53 SMAD4 PIK3CA KRAS CEACAM5 CDKN2A
27	spindle cell sarcoma	30.3	SERPINA3 MUC1 KRT7
28	necrotizing sialometaplasia	30.3	TP63 TP53 KRT7 KRT5
29	lung squamous cell carcinoma	30.2	TP63 TP53 PIK3CA KRT19 KRAS EGFR
30	breast metaplastic carcinoma	30.2	MAML2 KRT7 KRT5 EGFR
31	adenoid squamous cell carcinoma	30.2	KRT8 KRT7 KRT5 KRT19
32	papilloma	30.2	TP63 TP53 KRT8 KRT7 KRT5 KRAS
33	syringocystadenoma papilliferum	30.2	SERPINA3 MUC1 KRT19 KRAS
34	squamous cell carcinoma	30.2	TP63 TP53 SMAD4 PIK3CA MUC1 KRT7
35	acinar cell carcinoma	30.2	TP53 SMAD4 SERPINA3 KRT7
36	endometrial adenocarcinoma	30.2	TP53 MUC1 KRT7 KRAS EGFR CDKN2A
37	cystic teratoma	30.2	TP53 NKX2-1 KRT7 KRAS CDKN2A
38	lymphoepithelioma-like carcinoma	30.1	MUC1 KRT8 KRT7 KRT19 EGFR
39	secretory meningioma	30.1	SERPINA3 MUC1 KRT7 CEACAM7 CEACAM5
40	in situ carcinoma	30.1	TP53 SERPINA3 PIK3CA MUC1 KRT8 KRT5
41	adenocarcinoma in situ	30.1	KRT7 KRAS EGFR CEACAM5 CDKN2A
42	large cell neuroendocrine carcinoma	30.1	NKX2-1 KRT7 EGFR
43	cystadenocarcinoma	30.1	TP53 SERPINA3 PIK3CA MUC1 KRT7 CEACAM5
44	papillary squamous carcinoma	30.1	KRT7 KRT5 EGFR CEACAM5 CDKN2A
45	carcinosarcoma	30.1	TP53 PIK3CA MUC1 KRT7 KRAS EGFR
46	cholangiocarcinoma	30.0	TP53 SMAD4 PIK3CA MUC4 MUC1 KRT8
47	endocervical adenocarcinoma	30.0	TP53 PIK3CA MUC1 KRT7 CEACAM5 CDKN2A
48	cervical squamous cell carcinoma	30.0	TP63 TP53 PIK3CA KRT8 KRAS EGFR
49	teratoma	30.0	TP53 NKX2-1 KRT7 KRAS CEACAM5 CDKN2A
50	villous adenoma	30.0	TP53 MUC1 KRT8 KRT7 KRAS CEACAM5

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:

Sources

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 13)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.64	EGFR KRAS MUC1 PIK3CA
2	Decreased viability	GR00055-A-2	9.64	EGFR KRAS MUC1 PIK3CA
3	Decreased viability	GR00055-A-3	9.64	KRAS
4	Decreased viability	GR00106-A-0	9.64	KRAS
5	Decreased viability	GR00221-A-1	9.64	EGFR KRAS PIK3CA
6	Decreased viability	GR00221-A-2	9.64	KRAS PIK3CA
7	Decreased viability	GR00221-A-4	9.64	EGFR PIK3CA
8	Decreased viability	GR00249-S	9.64	MUC1
9	Decreased viability	GR00301-A	9.64	KRAS
10	Decreased viability	GR00381-A-1	9.64	KRAS
11	Decreased viability	GR00402-S-2	9.64	PIK3CA
12	Decreased cell migration	GR00055-A-1	9.13	CTSD
13	Decreased cell migration	GR00055-A-3	9.13	EGFR PIK3CA

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

⁴⁶ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.33	AR CDKN2A CTSD EGFR KRAS KRT19
2	cardiovascular system	MP:0005385	10.3	AR CDKN2A EGFR KRAS KRT19 KRT8
3	digestive/alimentary	MP:0005381	10.3	AR CDKN2A CTSD EGFR KRAS KRT19
4	growth/size/body region	MP:0005378	10.29	AR CDKN2A CTSD EGFR KRAS KRT19
5	endocrine/exocrine gland	MP:0005379	10.24	AR CDKN2A CTSD EGFR KRAS KRT19
6	immune system	MP:0005387	10.23	AR CDKN2A CTSD EGFR KRAS KRT19
7	embryo	MP:0005380	10.21	AR CDKN2A EGFR KRAS KRT19 KRT8
8	integument	MP:0010771	10.21	AR CDKN2A CTSD EGFR KRAS KRT19
9	craniofacial	MP:0005382	10.14	AR EGFR KRAS KRT19 KRT5 SMAD4
10	liver/biliary system	MP:0005370	9.97	AR CDKN2A EGFR KRAS KRT19 KRT8
11	neoplasm	MP:0002006	9.96	AR CDKN2A EGFR KRAS KRT19 NKX2-1
12	limbs/digits/tail	MP:0005371	9.95	AR EGFR KRAS KRT5 SMAD4 TP53
13	muscle	MP:0005369	9.92	AR CDKN2A EGFR KRAS PIK3CA SMAD4
14	no phenotypic analysis	MP:0003012	9.76	CDKN2A EGFR KRAS KRT19 NKX2-1 PIK3CA
15	reproductive system	MP:0005389	9.7	AR CDKN2A EGFR KRAS KRT19 KRT8
16	skeleton	MP:0005390	9.32	AR CDKN2A EGFR KRAS KRT19 NKX2-1

Sources

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Gemcitabine

Approved

Phase 3

95058-81-4

60750

Topotecan

Approved, Investigational

Phase 3

119413-54-6, 123948-87-8

60700

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

60780 44424639

Fluorouracil

Approved

Phase 3

51-21-8

3385

Irinotecan

Approved, Investigational

Phase 3

97682-44-5, 100286-90-6

60838

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

5310940 9887054 6857599 43805

leucovorin

Approved

Phase 3

58-05-9

6006

Cisplatin

Approved

Phase 3

15663-27-1

84093 441203 2767

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Carboplatin

Approved

Phase 3

41575-94-4

10339178 498142 38904

Tirapazamine

Investigational

Phase 3

27314-97-2

Liposomal doxorubicin

Phase 3

31703

Antibiotics, Antitubercular

Phase 3

Anti-Bacterial Agents

Phase 3

Adjuvants, Immunologic

Phase 3

Hematinics

Phase 3

Epoetin alfa

Phase 3

113427-24-0

Antimetabolites

Phase 3

Micronutrients

Phase 3

topoisomerase I inhibitors

Phase 3

Antidotes

Phase 3

Trace Elements

Phase 3

Nutrients

Phase 3

Hormones

Phase 3

Protective Agents

Phase 3

Vitamins

Phase 3

Calcium, Dietary

Phase 3

Tubulin Modulators

Phase 3

Antimitotic Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Mitogens

Phase 3

Immunoglobulins

Phase 3

Antibodies

Phase 3

Antibodies, Monoclonal

Phase 3

Protein Kinase Inhibitors

Phase 3

Erlotinib Hydrochloride

Phase 3

183319-69-9

176871

insulin

Phase 3

Insulin, Globin Zinc

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Sunitinib

Approved, Investigational

Phase 2

341031-54-7, 557795-19-4

5329102

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Medroxyprogesterone acetate

Approved, Investigational

Phase 2

71-58-9

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Metformin

Approved

Phase 2

657-24-9

14219 4091

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Interventional clinical trials:

(show top 50) (show all 70)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial	Unknown status	NCT01414608	Phase 3	Carboplatin;Cisplatin;Paclitaxel
2	A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
3	A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy	Completed	NCT01365156	Phase 3
4	A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
5	Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer	Completed	NCT00017004	Phase 3	Cisplatin
6	A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
7	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Recruiting	NCT04340141	Phase 3	Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil
8	A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	Recruiting	NCT02466971	Phase 3	Cisplatin;Triapine
9	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)	Recruiting	NCT01101451	Phase 3	Cisplatin
10	Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer	Terminated	NCT01363466	Phase 3
11	Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology	Terminated	NCT00673049	Phase 3	CP 751,871 (Figitumumab);Erlotinib;Erlotinib
12	Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer	Terminated	NCT00596830	Phase 3	CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
13	A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
14	A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix	Completed	NCT01026792	Phase 2	Temsirolimus
15	A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix	Completed	NCT01266460	Phase 2
16	A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
17	A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
18	A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01132820	Phase 2	Cediranib Maleate
19	A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01011933	Phase 2	Selumetinib
20	A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
21	A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)	Completed	NCT01267253	Phase 2	Brivanib Alaninate
22	A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
23	A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium	Completed	NCT01210222	Phase 2
24	A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma	Completed	NCT00389974	Phase 2	sunitinib malate
25	A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma	Completed	NCT00025467	Phase 2	thalidomide
26	Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
27	A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers	Completed	NCT00126581	Phase 2	Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
28	A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus	Completed	NCT00064025	Phase 2	Medroxyprogesterone
29	A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
30	A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix	Completed	NCT00039442	Phase 2	Capecitabine
31	PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX	Completed	NCT02164461	Phase 1, Phase 2
32	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
33	A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA	Completed	NCT00369122	Phase 2	Cisplatin
34	A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
35	A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
36	A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer	Completed	NCT02921269	Phase 2	Atezolizumab
37	Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix	Completed	NCT00005965	Phase 2	bryostatin 1;cisplatin
38	Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma	Recruiting	NCT03469531	Phase 2	Nimotuzumab;Cisplatin
39	The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial	Recruiting	NCT02394652	Phase 2	Metformin;Cisplatin;FAZA
40	A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer	Active, not recruiting	NCT01935934	Phase 2	Cabozantinib S-malate
41	A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer	Active, not recruiting	NCT02257528	Phase 2
42	A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT00977574	Phase 2	Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
43	A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer	Active, not recruiting	NCT00334815	Phase 2	Cisplatin;Docetaxel;Etoposide
44	Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma: A Multicenter, Open-label, Randomized, Control Phase II Study（ARISE）	Not yet recruiting	NCT04354961	Phase 2	Almonertinib;Paclitaxel and carboplatin
45	A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC)	Not yet recruiting	NCT03834571	Phase 2	Carboplatin;Cisplatin;Paclitaxel
46	A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes (TIL) Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen	Suspended	NCT02133196	Phase 2	Aldesleukin;Fludarabine;Cyclophosphamide
47	A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer	Terminated	NCT00924066	Phase 2	Ixempra (Ixabepilone (BMS-247550) )
48	A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas	Terminated	NCT02868892	Phase 2	Pemetrexed
49	A Phase I/II Trial of Abraxane in Combination With Carboplatin, Erbitux and Intensity Modulated Radiation Therapy (IMRT)for Treatment of Locally Advanced Squamous Cancer of the Head and Neck	Terminated	NCT00570674	Phase 1, Phase 2	Abraxane;Erbitux;Carboplatin
50	A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma	Withdrawn	NCT01301612	Phase 2	Nimotuzumab;Cisplatin;Cisplatin

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Sources

Genetic Tests for Adenosquamous Carcinoma

Sources

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

⁴⁰

Cervix, Pancreas, Breast, Lung, Colon, Prostate, Ovary

Sources

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 1865)

#	Title	Authors	PMID	Year
1	Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. ⁶¹ ⁵⁴	Carvalho L	19859629	2009
2	Large cell carcinoma of the lung: an endangered species? ⁶¹ ⁵⁴	Pardo J...Lozano MD	19444077	2009
3	Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. ⁵⁴ ⁶¹	Diaz A...Montero E	19514842	2009
4	Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. ⁵⁴ ⁶¹	Longatto-Filho A...Reis RM	19563658	2009
5	Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining. ⁵⁴ ⁶¹	Ko CJ...McNiff JM	19278431	2009
6	Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. ⁵⁴ ⁶¹	Rossi G...Tamberi S	18992960	2009
7	Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). ⁵⁴ ⁶¹	Kobayashi N...Inayama Y	18836809	2008
8	Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. ⁵⁴ ⁶¹	Baltazar F...Schmitt FC	17581404	2007
9	Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. ⁵⁴ ⁶¹	Kang SM...Chang J	17186532	2007
10	Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. ⁶¹ ⁵⁴	Baker AC...Chhieng D	17090193	2006
11	The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer. ⁶¹ ⁵⁴	Altaner S...Kutlu K	17036524	2006
12	Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. ⁶¹ ⁵⁴	Toyooka S...Shimizu N	16187277	2006
13	Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon. ⁶¹ ⁵⁴	Fujita T...Komatsubara S	15864702	2005
14	Unique characteristics of rectal carcinoma cell lines derived from invasive carcinomas in ulcerative colitis patients. ⁵⁴ ⁶¹	Yamashita K...Okayasu I	15016319	2004
15	Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. ⁵⁴ ⁶¹	Molina R...Iglesias J	14610320	2003
16	Colliding primary lung cancers of adenosquamous carcinoma and large cell neuroendocrine carcinoma. ⁶¹ ⁵⁴	Yazawa T...Kitamura H	12558872	2003
17	Neuroendocrine marker expression in cervical carcinomas of non-small cell type. ⁵⁴ ⁶¹	Chavez-Blanco A...Duenas-Gonzalez A	12352185	2002
18	Primary adenosquamous carcinoma of the liver which produces granulocyte-colony-stimulating factor and parathyroid hormone related protein: association with leukocytosis and hypercalcemia. ⁵⁴ ⁶¹	Hayashi T...Yamazaki K	11506305	2001
19	Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. ⁵⁴ ⁶¹	Wang TY...Crum CP	11381365	2001
20	Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. ⁵⁴ ⁶¹	Tabata T...Hasumi K	11006578	2000
21	EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. ⁶¹ ⁵⁴	Lei W...Levitt ML	9588219	1998
22	Different angiogenic pathways in human cervical cancers. ⁶¹ ⁵⁴	Tokumo K...Kudo T	9454658	1998
23	Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. ⁵⁴ ⁶¹	Betz C...Muller-Hermelink HK	7671236	1995
24	Epidermal growth factor receptor (EGF-R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers. ⁶¹ ⁵⁴	Jasonni VM...Flamigni C	7654016	1995
25	Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. ⁵⁴ ⁶¹	Mandai M...Fukumoto M	7736397	1995
26	Hypercalcaemia in a patient with fatal adenosquamous carcinoma of the colon. ⁶¹ ⁵⁴	Links M...Diamond T	8107631	1994
27	Cathepsin-D expression in cervical carcinoma and its prognostic significance. ⁶¹ ⁵⁴	Mitchell KM...Smith D	8322451	1993
28	Immunocytologic diagnosis of small-cell lung cancer in imprint smears. ⁶¹ ⁵⁴	Tome Y...Shimosato Y	1656682	1991
29	[A parathyroid hormone related protein (PTHrP) implicated in hypercalcemia associated with malignancy: research of the PTHrP for novel hormonal tumor marker]. ⁶¹ ⁵⁴	Wada C...Ohtani H	2348564	1990
30	Use of ring-enhancement and focal necrosis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma on CT and MRI. ⁶¹	Schawkat K...Mortele KJ	33387918	2021
31	MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. ⁶¹	Potter R...EMBRACE Collaborative Group	33794207	2021
32	Cervical cancer in women under 30 years of age in Norway: a population-based cohort study. ⁶¹	Gravdal BH...Bjorge T	33736628	2021
33	The baseline recurrence risk of patients with intermediate-risk cervical cancer. ⁶¹	Yoneoka Y...Kato T	33752280	2021
34	Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. ⁶¹	Matsuo K...Wright JD	33771396	2021
35	Cervical conization and lymph node assessment for early stage low-risk cervical cancer. ⁶¹	Nica A...Covens A	33649012	2021
36	Molecular mechanisms of An-Chuan Granule for the treatment of asthma based on a network pharmacology approach and experimental validation. ⁶¹	Chen XL...Zhu QY	33645621	2021
37	PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions. ⁶¹	Lee SM...Sung CO	33773917	2021
38	Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix. ⁶¹	Takayanagi D...Yoshida H	33802174	2021
39	Adenosquamous carcinoma: An aggressive histologic sub-type of colon cancer with poor prognosis. ⁶¹	Nasseri Y...Gangi A	32862977	2021
40	Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort. ⁶¹	Yoo J...Han JK	33787974	2021
41	Characteristics and survival prognosis of patients with pure squamous cell carcinoma of the gallbladder. ⁶¹	Zhu C...Zhou Y	33236449	2021
42	Clinical and Histological Basis of Adenosquamous Carcinoma of the Pancreas: A 30-year Experience. ⁶¹	Moslim MA...Reddy SS	33190924	2021
43	Human papillomavirus-related head and neck adenosquamous carcinoma: A systematic review and individual patient data meta-analysis. ⁶¹	Fiacchini G...Bruschini L	33685817	2021
44	Updates on World Health Organization classification and staging of esophageal tumors: implications for future clinical practice. ⁶¹	Lam AK	33157124	2021
45	NTRK fusion-positive colorectal cancer in Japanese population. ⁶¹	Yonemaru J...Sekine S	33631044	2021
46	Adenosquamous carcinoma of the breast, an uncommon diagnosis with poor prognosis-Lessons learned from a 12-year analysis of the National Cancer Database. ⁶¹	Cochrane K...Orucevic A	33482684	2021
47	Esophageal superficial adenosquamous carcinoma resected by endoscopic submucosal dissection: A rare case report. ⁶¹	Liu GY...Tian Y	33644200	2021
48	Pancreatic panniculitis in a patient with pancreatic adenosquamous carcinoma. ⁶¹	Ariga H...Takayashiki N	33124679	2021
49	An Australian, single-centre study of surgical management outcomes for early-stage cervical cancer. ⁶¹	Weishaupt J...Carter J	33176013	2021
50	A population-based analysis of adenosquamous carcinoma of the salivary gland. ⁶¹	Han H...Shao LQ	33708547	2021

Sources

Genes for Adenosquamous Carcinoma

Genes related to Adenosquamous Carcinoma (0 elite genes):

(show all 28)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	EGFR	Epidermal Growth Factor Receptor	Protein Coding	21.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	17186532 19563658 7528164 (more) 8459036 7654016 17581404 18992960 17069674 19514842 17238183 9588219 16187277
2	KRT7	Keratin 7	Protein Coding	21.18	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19278431 19444077 19859629
3	TP63	Tumor Protein P63	Protein Coding	20.58	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19278431 12210069 11381365 (more) 16484002 19444077
4	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	19.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	17090193
5	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	18.8	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	14610320
6	KRT8	Keratin 8	Protein Coding	18.79	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	1715731 1724841
7	KRT19	Keratin 19	Protein Coding	17.38	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	19444077
8	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	16.34	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	17425390 17090193
9	CEACAM7	CEA Cell Adhesion Molecule 7	Protein Coding	14.38	Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	1700970 11006578
10	KRT5	Keratin 5	Protein Coding	14.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	14.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	AR	Androgen Receptor	Protein Coding	13.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	12558872
13	TP53	Tumor Protein P53	Protein Coding	13.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	SERPINA3	Serpin Family A Member 3	Protein Coding	13.7	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
15	NKX2-1	NK2 Homeobox 1	Protein Coding	13.47	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	17036524 11224607 15084379 (more) 19444077
16	CTSD	Cathepsin D	Protein Coding	13.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8322451
17	MAML2	Mastermind Like Transcriptional Coactivator 2	Protein Coding	13.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	13.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	12.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	SMAD4	SMAD Family Member 4	Protein Coding	12.62	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	SYP	Synaptophysin	Protein Coding	12.59	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	PTEN	Phosphatase And Tensin Homolog	Protein Coding	12.41	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	CRTC1	CREB Regulated Transcription Coactivator 1	Protein Coding	12.34	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
24	CD274	CD274 Molecule	Protein Coding	12.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	KRT18	Keratin 18	Protein Coding	11.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
26	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	11.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
27	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	11.73	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
28	IVL	Involucrin	Protein Coding	11.72	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴	1737626

Sources

Variations for Adenosquamous Carcinoma

Sources

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Sources

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 35)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁵ Show member pathways Axon guidance ⁶⁵	13.46	SMAD4 PIK3CA KRT8 KRT7 KRT5 KRT19
2	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.65	TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
3	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.64	TP53 PIK3CA KRAS EGFR CDKN2A
4	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁶ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²³ Apoptosis Signaling Pathways ⁶⁴	12.56	TP63 TP53 PIK3CA KRAS CTSD CDKN2A
5	Pathways in cancer ³⁶	12.53	TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
6	Cytoskeletal Signaling ⁴	12.48	MUC1 KRT8 KRT7 KRT5 KRT19
7	VEGF Signaling ⁶⁶ Show member pathways EGFR Signaling Pathway ⁶⁶ VEGF Signaling Pathway ⁶⁰	12.31	TP53 MUC1 KRAS EGFR
8	MicroRNAs in cancer ³⁶	12.29	TP63 TP53 PIK3CA KRAS EGFR CDKN2A
9	Translation Non-genomic (rapid) action of Androgen Receptor ²³ Show member pathways Basal cell carcinoma ³⁶ Transcription Androgen Receptor nuclear signaling ²³	12.28	TP53 PIK3CA EGFR AR
10	Development EGFR signaling pathway ²³ Show member pathways Development ERBB-family signaling ²³ EGF Pathway ⁶³ ErbB receptor signaling network ¹	12.27	PIK3CA MUC1 KRAS EGFR
11	Proteoglycans in cancer ³⁶	12.26	TP53 PIK3CA KRAS EGFR
12	Viral carcinogenesis ³⁶	12.26	TP53 PIK3CA KRAS CDKN2A
13	Human T-cell leukemia virus 1 infection ³⁶	12.22	TP53 SMAD4 PIK3CA KRAS CDKN2A
14	Endometrial cancer ³⁶ Show member pathways Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.19	TP53 SMAD4 PIK3CA KRAS EGFR CDKN2A
15	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁴ Show member pathways Akt Signaling Pathway ⁶⁴	12.18	TP53 PIK3CA KRAS EGFR AR
16	Colorectal Cancer Metastasis ⁶³	12.15	TP53 SMAD4 KRAS EGFR
17	Cellular senescence (KEGG) ³⁶	12.12	TP53 PIK3CA KRAS CDKN2A
18	FoxO signaling pathway ³⁶ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.04	SMAD4 PIK3CA KRAS EGFR
19	Direct p53 effectors ¹	12.01	TP63 TP53 EGFR CTSD
20	Integrated Breast Cancer Pathway ¹	11.95	TP53 SMAD4 KRAS EGFR AR
21	Sphingolipid signaling pathway ³⁶	11.94	TP53 PIK3CA KRAS CTSD
22	Glioblastoma Multiforme ⁶³	11.89	TP53 KRAS EGFR CDKN2A
23	Cytoskeleton remodeling Neurofilaments ²³ Show member pathways Cytoskeleton remodeling Keratin filaments ²³	11.87	KRT8 KRT7 KRT5 KRT19
24	Platinum drug resistance ³⁶	11.71	TP53 PIK3CA CDKN2A
25	Estrogen signaling pathway (KEGG) ³⁶	11.69	PIK3CA KRT19 KRAS EGFR CTSD
26	TGF-beta Signaling Pathway (sino) ⁶⁶	11.68	SMAD4 PIK3CA KRAS
27	Bladder cancer ³⁶ ¹	11.6	TP53 KRAS EGFR CDKN2A
28	Central carbon metabolism in cancer ³⁶	11.55	TP53 PIK3CA KRAS EGFR
29	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.52	TP53 EGFR CDKN2A
30	LKB1 signaling events ¹	11.41	TP53 SMAD4 CTSD
31	Signaling mediated by p38-alpha and p38-beta ¹	11.3	TP53 KRT8 KRT19
32	Extracellular vesicle-mediated signaling in recipient cells ¹	11.21	SMAD4 KRAS EGFR
33	G-protein signaling_K-RAS regulation pathway ²³	11.13	PIK3CA KRAS EGFR
34	DNA Damage Response (only ATM dependent) ¹	11.08	TP53 SMAD4 PIK3CA KRAS CDKN2A
35	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁵	11.01	TP63 TP53 CDKN2A

Sources

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular exosome	GO:0070062	9.28	SERPINA3 MUC4 MUC1 KRT8 KRT7 KRT5
2	intermediate filament	GO:0005882	9.26	KRT8 KRT7 KRT5 KRT19

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.85	TP53 NKX2-1 KRAS CDKN2A AR
2	keratinization	GO:0031424	9.67	KRT8 KRT7 KRT5 KRT19
3	Ras protein signal transduction	GO:0007265	9.58	TP53 KRAS CDKN2A
4	positive regulation of transcription by RNA polymerase II	GO:0045944	9.56	TP63 TP53 SMAD4 NKX2-1 MAML2 EGFR
5	cornification	GO:0070268	9.46	KRT8 KRT7 KRT5 KRT19
6	Leydig cell differentiation	GO:0033327	9.43	NKX2-1 AR
7	positive regulation of transcription from RNA polymerase II promoter in response to stress	GO:0036003	9.32	TP53 MUC1
8	cell differentiation involved in embryonic placenta development	GO:0060706	9.26	KRT8 KRT19
9	positive regulation of transcription, DNA-templated	GO:0045893	9.17	TP63 TP53 SMAD4 NKX2-1 EGFR CDKN2A

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin binding	GO:0003682	9.72	TP63 TP53 SMAD4 EGFR AR
2	transcription regulatory region sequence-specific DNA binding	GO:0000976	9.55	TP63 TP53 SMAD4 NKX2-1 AR
3	RNA polymerase II transcription factor binding	GO:0001085	9.43	TP53 SMAD4 AR
4	p53 binding	GO:0002039	9.26	TP63 TP53 MUC1 CDKN2A
5	MDM2/MDM4 family protein binding	GO:0097371	8.8	TP63 TP53 CDKN2A

Sources

Sources for Adenosquamous Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 20-May-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia